Thr1613

Site Information
PPsySsRtPGtPGtP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4704347
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 6 ) , non-small cell lung cancer ( 6 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , Calu 6 (pulmonary) ( 6 ) , DMS79 (pulmonary) ( 4 ) , H2009 (pulmonary) ( 6 ) , H2077 (pulmonary) ( 6 ) , H2887 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC1359 (pulmonary) ( 6 ) , HCC2279 (pulmonary) ( 6 ) , HCC4006 (pulmonary) ( 6 ) , HCC78 (pulmonary) ( 5 ) , HCC827 (pulmonary) ( 6 ) , HOP62 (pulmonary) ( 6 ) , LCLC-103H (pulmonary) ( 6 ) , LOU-NH91 (squamous) ( 6 ) , lung ( 4 , 5 ) , NCI-H128 (pulmonary) ( 4 ) , NCI-H1395 (pulmonary) ( 6 ) , NCI-H1417 (pulmonary) ( 4 ) , NCI-H1648 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 6 ) , NCI-H209 (pulmonary) ( 4 ) , NCI-H2172 (pulmonary) ( 6 ) , NCI-H2228 (pulmonary) ( 5 ) , NCI-H3122 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 6 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H520 (squamous) ( 6 ) , NCI-H524 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 5 ) , PC9 (pulmonary) ( 6 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 3 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	LRRK2-IN-1 ( 3 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info